Rogers Jane E
Pharmacy Clinical Programs, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Onco Targets Ther. 2017 Apr 7;10:2033-2044. doi: 10.2147/OTT.S115430. eCollection 2017.
Epidermal growth factor receptor (EGFR) is overexpressed in many malignancies, including colorectal cancer (CRC), making EGFR an attractive treatment option. Panitumumab and cetuximab, monoclonal antibodies (mAbs) directed at EGFR, are both currently utilized in the management of metastatic CRC (mCRC). Through the development of these agents in mCRC, key issues surrounding each mAbs use have been revealed. These key issues include negative patient outcome avoidance when determining use, the economic burden with high-cost medication, predictive biomarkers, tumor location, patient geographic location, patient quality of life, and the prevention of debilitating adverse effects. CRC remains a common malignancy, with many of these patients expected to receive targeted therapy, including EGFR mAb therapy. Oncologists must recognize these EGFR mAb factors in order to improve outcomes. This review aims to provide a chronological timeline on the development of panitumumab, clinical pearls, and guidance on the current use of panitumumab in mCRC.
表皮生长因子受体（EGFR）在包括结直肠癌（CRC）在内的许多恶性肿瘤中均有过表达，这使得EGFR成为一个有吸引力的治疗选择。帕尼单抗和西妥昔单抗这两种针对EGFR的单克隆抗体（mAbs）目前都用于转移性结直肠癌（mCRC）的治疗。通过在mCRC中开发这些药物，围绕每种mAb使用的关键问题已被揭示。这些关键问题包括在确定使用时避免患者预后不良、高成本药物带来的经济负担、预测性生物标志物、肿瘤位置、患者地理位置、患者生活质量以及预防使人衰弱的不良反应。CRC仍然是一种常见的恶性肿瘤，这些患者中的许多人预计将接受靶向治疗，包括EGFR mAb治疗。肿瘤学家必须认识到这些EGFR mAb因素，以改善治疗效果。本综述旨在提供帕尼单抗开发的时间线、临床要点以及目前帕尼单抗在mCRC中使用的指导。
